Biogen Inc (BIIB) Shares Bought by Public Employees Retirement System of Ohio
Public Employees Retirement System of Ohio grew its position in shares of Biogen Inc (NASDAQ:BIIB) by 0.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 147,021 shares of the biotechnology company’s stock after buying an additional 520 shares during the period. Public Employees Retirement System of Ohio owned about 0.07% of Biogen worth $46,035,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Atlantic Trust LLC acquired a new stake in shares of Biogen during the 2nd quarter worth approximately $114,000. Horan Capital Advisors LLC. acquired a new stake in shares of Biogen during the 3rd quarter worth approximately $128,000. Massey Quick Simon & CO. LLC raised its position in shares of Biogen by 84.8% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 195 shares during the period. Gs Investments Inc. acquired a new stake in shares of Biogen during the 2nd quarter worth approximately $136,000. Finally, Thompson Siegel & Walmsley LLC raised its position in shares of Biogen by 33.3% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 528 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 132 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.
Biogen Inc (NASDAQ:BIIB) opened at $323.55 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19. The stock has a market capitalization of $69,311.55, a price-to-earnings ratio of 15.18, a price-to-earnings-growth ratio of 2.05 and a beta of 0.73. Biogen Inc has a one year low of $244.28 and a one year high of $348.84.
A number of brokerages have recently weighed in on BIIB. Royal Bank of Canada reiterated a “hold” rating and set a $321.00 price target on shares of Biogen in a research report on Tuesday, December 5th. Mizuho set a $400.00 price target on Biogen and gave the stock a “buy” rating in a research report on Monday, November 13th. Vetr cut Biogen from a “buy” rating to a “hold” rating and set a $316.82 price target on the stock. in a research report on Monday, September 4th. Morgan Stanley upgraded Biogen from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $311.00 to $375.00 in a research report on Thursday, October 5th. Finally, ValuEngine cut Biogen from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Twelve analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $344.60.
In other news, Director Alexander J. Denner purchased 30,000 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was purchased at an average cost of $317.36 per share, with a total value of $9,520,800.00. Following the purchase, the director now owns 10,029 shares in the company, valued at approximately $3,182,803.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.25% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Biogen Inc (BIIB) Shares Bought by Public Employees Retirement System of Ohio” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/15/biogen-inc-biib-shares-bought-by-public-employees-retirement-system-of-ohio.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Stock Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related stocks with our FREE daily email newsletter.